Rasadokht Forati,Deborah Bartz
Rasadokht Forati
Isaac S Kohane
Isaac S Kohane
Hiddo J L Heerspink,Meg Jardine,Donald E Kohan et al.
Hiddo J L Heerspink et al.
Background: Patients with IgA nephropathy and severe proteinuria have a high lifetime risk of kidney failure. The efficacy and safety of the selective endothelin type A receptor antagonist atrasentan in reducing proteinur...
EMPA-KIDNEY Collaborative Group;William G Herrington,Natalie Staplin,Nikita Agrawal et al.
EMPA-KIDNEY Collaborative Group;William G Herrington et al.
Background: In the EMPA-KIDNEY trial, empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, had positive cardiorenal effects in patients with chronic kidney disease who were at risk for disease progression. P...
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy [0.03%]
IgA肾病患者补体替代途径的抑制剂Iptacopan
Vlado Perkovic,Jonathan Barratt,Brad Rovin et al.
Vlado Perkovic et al.
Background: The alternative complement pathway plays a key role in the pathogenesis of IgA nephropathy. Iptacopan specifically binds to factor B and inhibits the alternative pathway. ...
Way Stations in Progress - Burgeoning Treatment Options for IgA Nephropathy [0.03%]
进行中的停靠站——IgA肾病治疗选择的现状及未来展望
Julie R Ingelfinger
Julie R Ingelfinger
Marta Sablik,Aurélie Sannier,Marc Raynaud et al.
Marta Sablik et al.
Background: The heterogeneous clinical presentation of graft microvascular inflammation poses a major challenge to successful kidney transplantation. The effect of microvascular inflammation on allograft outcomes is uncle...
Danny M Cohn,Padmalal Gurugama,Markus Magerl et al.
Danny M Cohn et al.
Background: Hereditary angioedema is a rare genetic disease characterized by severe and unpredictable swelling attacks. NTLA-2002 is an in vivo gene-editing therapy that is based on clustered regularly interspaced short p...
Kiran Musunuru
Kiran Musunuru
Parkinson's Disease. Reply [0.03%]
帕金森病。回复信
Caroline M Tanner,Jill L Ostrem
Caroline M Tanner